Hormonal
Transfeminine hormone therapy (estrogen + antiandrogens) induces feminizing physical changes including breast development, fat redistribution, and reduced body/facial hair, but does not significantly alter voice pitch.
Transfeminine hormone therapy will cause breast growth, fat redistribution to a female pattern, and reduced body/facial hair growth. It will NOT significantly lower your voice pitch. If voice pitch change is a priority, you will likely need voice training or surgery in addition to hormones. Breast development varies, with many reaching a plateau at a smaller cup size (AAA or less) within 6 months.
Feminizing treatment with estrogens and antiandrogens has desired physical changes, such as enhanced breast growth, reduction of facial and body hair growth, and fat redistribution in a female pattern... Transgender women will have an improved self-perceived feminine quality in their voice after the initiation of hormone therapy. However, many transgender women still have difficulty with their voice quality...
Why this rating
Based on cohort studies (Italian, German, UK, US) showing consistent trends in body composition and breast development.
Source
Endocrinology of Transgender Medicine
Guy T’Sjoen et al. · Endocrine Reviews · 2018
DOI 10.1210/er.2018-00011
More from this paper
- Gender-affirming hormone therapy significantly reduces mental health morbidity, including depression and anxiety, in transgender individuals.Good
- Transfeminine hormone therapy is associated with an increased risk of venous thromboembolism (VTE), particularly with oral ethinyl estradiol or conjugated equine estrogen, whereas transdermal estradiol may mitigate this risk.Moderate
- Testosterone therapy in transgender men is associated with virilization (deepening voice, increased muscle mass, cessation of menses) and is considered safe regarding cardiovascular and oncological disease in the short- to mid-term.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →